(Q54541278)

English

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

object named as

Ignace Vergote

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Frédéric Amant

2

object named as

Frederic Amant

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

author name string

Walter H Gotlieb

1

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Suresh Advani

3

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Chanchal Goswami

4

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Hal Hirte

5

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Diane Provencher

6

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Naresh Somani

7

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

S Diane Yamada

8

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Jean-Francois Tamby

9

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

publication date

20 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

13

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

2

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

154-162

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biology of vascular endothelial growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Markedly elevated levels of vascular endothelial growth factor in malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of single voided urine samples to estimate quantitative proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970338-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70338-2

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 May 2018

http://europepmc.org/abstract/MED/22192729

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54541278&oldid=1508999991"